THPOR, MPL, TPOR, Myeloproliferative leukemia protein, Myeloproliferative Leukemia Virus Oncogene, Proto-Oncogene C-Mpl, TPO-R, CD110 Antigen, THCYT2, C-MPL, CD110, MPLV, Receptors, Thrombopoietin, MPL Proto-Oncogene, Thrombopoietin Receptor, Thrombopoietin Receptor


c-MPL is the receptor for thrombopoietin (TPO), the main megakaryocyte (MK) growth factor, and c-Mpl is believed to be expressed on cells of the hematopoietic lineage. Receptor for thrombopoietin that acts as a primary regulator of megakaryopoiesis and platelet production. May represent a regulatory molecule specific for TPO-R-dependent immune responses.

KO Status


Drug Information

Launched drugs: 6
Drugs in clinical trials: 8
Latest Research Phase: Approved

Drug Name





Clinical Trials




Shionogi & Co Ltd

Purpura, Thrombocytopenic, Idiopathic, Liver Diseases, Thrombocytopenia

Recombinant human thrombopoietin

rhTPO (3SBio)


Shenyang Sunshine Pharmaceutical Co Ltd

Purpura, Thrombocytopenic, Idiopathic, Liver Cirrhosis, Thrombocytopenia

Eltrombopag Diolamine

SB-497115-GR, ETB-115, SB-497115


Glaxosmithkline Plc

Purpura, Thrombocytopenic, Idiopathic, HIV Infections, Leukemia, Non-alcoholic Fatty Liver Disease, Purpura, Myelodysplastic Syndromes, Liver Cirrhosis, Liver Diseases, Delayed Graft Function, Anemia, Aplastic, Hepatitis B, Hepatitis C, Thrombocytopenia, Hepatitis C, Chronic


AMP-2, AMG-531


Amgen Inc

Purpura, Thrombocytopenic, Idiopathic, Solid tumours, Myelodysplastic Syndromes, Myeloproliferative Disorders, Hodgkin Disease, Anemia, Aplastic, Acute Radiation Syndrome, Lung Neoplasms, Thrombocytopenia, Purpura, Thrombocytopenic, Lymphoma, Non-Hodgkin, Carcinoma, Non-Small-Cell Lung

Avatrombopag Maleate

E-5501, YM-477, AKR-501, AS-1670542, AKR-501-monomaleate


Astellas Pharma Inc

Purpura, Thrombocytopenic, Idiopathic, Liver Diseases, Cardiovascular Diseases, Thrombocytopenia

Recombinant human thrombopoietin biosimilar (Biolotus)




Herombopag Olamine



Jiangsu Hengrui Medicine Co Ltd

Purpura, Thrombocytopenic, Idiopathic, Anemia, Aplastic, Thrombocytopenia

Romiplostim biosimilar (Intas Pharmaceuticals)

Phase 3 Clinical

Intas Biopharmaceuticals

Purpura, Thrombocytopenic, Idiopathic

Romiplostim biosimilar (Enzene Biosciences)


Phase 3 Clinical

Enzene Biosciences

Purpura, Thrombocytopenic, Idiopathic

Recombinant human thrombopoietin mimetic-fusion protein (Qilu Pharmaceutical)


Phase 3 Clinical

Qilu Pharmaceutical Co Ltd

Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia





The DNA sequence and biological annotation of human chromosome 1

Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., Bentley D.R.,

Nature 441:315-321(2006)

Ubiquitination and degradation of the thrombopoietin receptor c-Mpl

Saur S.J., Sangkhae V., Geddis A.E., Kaushansky K., Hitchcock I.S.,

Blood 115:1254-1263(2010)

Characterization of single-nucleotide polymorphisms in coding regions of human genes

Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N., Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L., Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q., Lander E.S.,

Nat. Genet. 22:231-238(1999)

Cloning and characterization of a family of proteins associated with Mpl

Meunier C.F., Bordereaux D., Porteu F., Gisselbrecht S., Chretien S., Courtois G.,

J. Biol. Chem. 277:9139-9147(2002)

Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin

Ding J., Komatsu H., Wakita A., Kato-Uranishi M., Ito M., Satoh A., Tsuboi K., Nitta M., Miyazaki H., Iida S., Ueda R.,

Blood 103:4198-4200(2004)

Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis

Moliterno A.R., Williams D.M., Gutierrez-Alamillo L.I., Salvatori R., Ingersoll R.G., Spivak J.L.,

Proc. Natl. Acad. Sci. U.S.A. 101:11444-11447(2004)

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

Pardanani A.D., Levine R.L., Lasho T., Pikman Y., Mesa R.A., Wadleigh M., Steensma D.P., Elliott M.A., Wolanskyj A.P., Hogan W.J., McClure R.F., Litzow M.R., Gilliland D.G., Tefferi A.,

Blood 108:3472-3476(2006)

MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease

Germeshausen M., Ballmaier M., Welte K.,

Hum. Mutat. 27:296-296(2006)

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

Pikman Y., Lee B.H., Mercher T., McDowell E., Ebert B.L., Gozo M., Cuker A., Wernig G., Moore S., Galinsky I., DeAngelo D.J., Clark J.J., Lee S.J., Golub T.R., Wadleigh M., Gilliland D.G., Levine R.L.,

PLoS Med. 3:E270-E270(2006)

The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity

Ding J., Komatsu H., Iida S., Yano H., Kusumoto S., Inagaki A., Mori F., Ri M., Ito A., Wakita A., Ishida T., Nitta M., Ueda R.,

Blood 114:3325-3328(2009)